Detailed information
| LncRNA Name | MIR2052HG |
| Variant Type | SNP |
| Variant ID | MA.27 |
| Species | human |
| Circulating | ✕ |
| Survival | ✕ |
| CeRNA | ✕ |
| Methylation | ✕ |
| Enhancer | ✕ |
| Drug | ✕ |
| Disease/Trait | hepatocellular carcinoma |
| LncRNA Target Gene | LMTK3 |
| Tissue | tissue |
| Experiment | luciferase activity assay,RNA-binding protein immunoprecipitation,Chromatin immunoprecipitation (ChIP),western blotting,qRT-PCR |
| Function Description | The variant SNP increased EGR1 binding to LMTK3 promoter in response to androstenedione, relative to wild-type genotype, a pattern that can be reversed by aromatase inhibitor treatment. LMTK3 |
| Pubmed ID | 30944027 |
| Year | 2019 |
| Title | The lncRNA MIR2052HG regulates ERα levels and aromatase inhibitor resistance through LMTK3 by recruiting EGR1 |
| External Links | |
|---|---|
| Links For MIR2052HG | GeneCards HGNC NONCODE LncRNAWiki lncrnadb |
| Links For hepatocellular carcinoma | OMIM Cosmic |
| Links For MA.27 | dbSNP ClinVar OMIM |